Abstract
Background: Melasma is a chronic relapsing pigmentary disorder in which ultraviolet and visible-light exposure may contribute to melanogenic signaling partly through oxidative stress. Objective: To describe exploratory clinical and tolerability observations during use of an HPR/retinol-based serum with tinted sunscreen containing Polypodium leucotomos extract. Methods: Thirty adults with melasma and Fitzpatrick skin types III–IV entered this single-arm prospective study. Serum was used nightly for 8 weeks and sunscreen daily for 12 weeks. Primary outcomes in the pre-enrollment protocol were Antera3D pigmentation and Mexameter melanin and erythema indices; physician-assessed severity and biophysical measures were secondary. Registration occurred after study completion. Results: Twenty-seven participants completed follow-up. At month 3, reported mean Antera3D pigmentation decreased from 46.63 to 44.57, Mexameter melanin index from 262.90 to 224.60, and mMASI from 7.80 to 6.32, corresponding to descriptive reductions of 4.4%, 14.6%, and 19.0% in the respective group means. Reported p values were exploratory. Increased Cutometer R0 indicated greater deformation under suction and did not establish improved firmness or elasticity. Ten participants reported local irritation; no moderate or severe adverse events or adverse-event-related discontinuations were reported. Conclusion: Modest within-cohort changes were observed. The uncontrolled concurrent-intervention design cannot establish efficacy, comparative effectiveness, synergy, or the contribution of either product or individual ingredient. These observations are hypothesis-generating; antioxidant-mediated efficacy cannot be inferred.
Keywords:
melasma; Polypodium leucotomos; oxidative stress; antioxidants; photoprotection; retinoids